Bioinvent
BioInvent International is a Swedish research, pharmaceutical and life science company with focus on clinical development of antibody drugs for immunotherapy against cancer.[1] The company was founded in 1983 by Carl Borrebaeck and is listed on the Stockholm Stock Exchange since 2001. [citation needed]The company's partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. Martin Welschof has been CEO since 2018.[2][3][4][5][6][7]
References
- ^ Maria Phillips, "Bioinvent rasar efter emissionsbesked", Dagens industri, 25 February 2019 (in Swedish).
- ^ "BioInvent rekryterar Martin Welschof som ny vd" (press release), Cision, 12 April 2018 (in Swedish).
- ^ "BioInvent International", Avanza Bank, retrieved 19 June 2019 (in Swedish).
- ^ "Technology", Bioinvent, retrieved 19 June 2019.
- ^ Kajsa-Stina Kalin, "Bioinvent var pionjärer i parken" Sydsvenskan, 4 October 2015 (in Swedish).
- ^ Maria Lindh, "Forskningen som ledde till miljardavtalet", LUM., Lund University, 11 September 2015 (in Swedish).
- ^ "Bioinvent i nytt cancer–samarbete", Dagens Nyheter, 4 January 2012 (in Swedish; subscription required).